Latest Content

Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.

The FDA received a BLA for etentamig in relapsed/refractory multiple myeloma, based on response and PFS gains in the phase 3 CERVINO trial.

Judy E. Garber, MD, MPH, of the Dana Farber Cancer Institute is the recipient of the 2026 Basser Global Prize.

The European Commission approved T-DXd for patients with HER2+ breast cancer who have residual invasive disease after neoadjuvant treatment.

Elranatamab improved PFS vs 3 standard regimens in relapsed/refractory multiple myeloma in the phase 3 MagnetisMM-32 trial.

INCB161734 plus chemotherapy was tolerable and elicited responses in updated data from a trial of patients with KRAS G12D–mutated pancreatic cancer.

Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.

Longer DeLLphi-304 follow-up showed sustained OS, PFS, and response durability with tarlatamab in second-line small cell lung cancer.

Rinatabart sesutecan significantly improved PFS and OS vs investigator’s-choice chemotherapy in platinum-resistant ovarian cancer.

Sac-TMT extended survival and improved response rates vs chemotherapy in endometrial cancer that had progressed after chemotherapy and immunotherapy.

KEYNOTE-412 ctDNA data tie early clearance to longer survival with pembrolizumab plus chemoradiotherapy in HPV-negative head and neck cancer.

Single-agent pembrolizumab extended progression-free survival vs carboplatin and paclitaxel in mismatch repair–deficient endometrial cancer.

Frontline savolitinib plus osimertinib improved progression-free survival vs osimertinib alone in EGFR-mutated, MET-overexpressing lung cancer.

The FDA approved talazoparib plus enzalutamide for HRR-positive, metastatic androgen pathway modulation–naive or -sensitive prostate cancer.

The next-generation, whole genome, tumor-informed Oncodetect MRD test tracks up to 5000 variants vs up to 200 in the first-generation assay.

Risvutatug rezetecan delayed progression vs gemcitabine and docetaxel in patients with osteosarcoma after 2 or more prior systemic therapies.

A new clinical trial will investigate whether a simple blood test could help detect breast cancer as early as Stage I.

Phase 3 data showed a significant PFS improvement with trastuzumab pamirtecan vs chemotherapy in HR-positive, HER2-low metastatic breast cancer.

The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.

The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.

Adding niraparib and dostarlimab to definitive CRT improved 1-year PFS in cisplatin-fit patients, although toxicity drove frequent discontinuations.

Updated FONTANA data show torvu-sam activity across FRα expression levels in platinum-resistant ovarian cancer.

In HARMONi-GI1, ivonescimab plus chemotherapy extended survival over durvalumab plus chemotherapy in untreated advanced biliary tract cancer.

Sonesitatug vedotin is a potential new SOC in select Claudin 18.2–positive gastroesophageal carcinoma.

Divarasib extended survival over first-generation KRAS G12C inhibitors in a head-to-head phase 3 trial in previously treated lung cancer.

In SAFFRON, the oral EGFR/MET inhibitor pairing extended survival over platinum/pemetrexed in MET-driven lung cancer that progressed on osimertinib.

Tovecimig plus paclitaxel improved objective response over paclitaxel alone in previously treated advanced biliary tract cancer in COMPANION-002.

Adding LK101 to tislelizumab-based first-line maintenance yielded early antitumor activity and signs of immune activation in advanced NSCLC.

Adding durvalumab and enfortumab vedotin around cystectomy extended survival in muscle-invasive bladder cancer without cisplatin options.

Adding pembrolizumab to adjuvant radiation did not meet prespecified superiority criteria in patients with stage I/II high-intermediate–risk dMMR endometrioid endometrial cancer in the phase 3 NRG-GY020 trial.

Adding tarlatamab-dlle to durvalumab maintenance extended survival in extensive-stage small cell lung cancer in the phase 3 DeLLphi-305 trial.

Adding intismeran autogene to pembrolizumab cut the risk of recurrence and distant metastasis in resected high-risk melanoma in INTerpath-001.

Adding darolutamide to androgen deprivation and primary or salvage radiation lowered metastasis risk in very high-risk localized prostate cancer.

INCA33890 combined with standard-of-care therapy produced responses in first- and third-line metastatic microsatellite stable colorectal cancer.

An exploratory TROPION-Breast02 analysis showed CNS PFS and intracranial response benefits with datopotamab deruxtecan in TNBC with brain metastases.

Adding durvalumab to BCG induction and maintenance reduced high-risk recurrences in patients with papillary-only bladder tumors in POTOMAC.

Interim DUO-E data showed longer median survival with chemotherapy plus durvalumab and olaparib maintenance that did not reach significance.

Perioperative enfortumab vedotin plus pembrolizumab showed no clinically meaningful HRQOL detriment in cisplatin-eligible MIBC.

Circulating tumor DNA findings from CROWN tied TP53 status and tumor fraction to outcomes with first-line lorlatinib in ALK-positive lung cancer.

Neoadjuvant T-DXd produced faster imaging responses vs ddAC in DESTINY-Breast11, but imaging poorly predicted pCR.

Abemaciclib plus fulvestrant showed a numerical yet nonsignificant overall survival trend after CDK4/6 inhibitor progression in final postMONARCH data.

INCB123667 with bevacizumab showed antitumor activity in heavily pretreated, cyclin E1–overexpressing platinum-resistant ovarian cancer.

Selective CDK4 inhibitor atirmociclib plus fulvestrant reduced risk of progression or death by 40% vs investigator's choice of therapy in the phase 2 FOURLIGHT-1 trial.